4.7 Article

Impact of vitamin D receptor activity on experimental autoimmune prostatitis

期刊

JOURNAL OF AUTOIMMUNITY
卷 32, 期 2, 页码 140-148

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jaut.2009.02.002

关键词

Prostatitis; Autoimmunity; Vitamin D; Immunomodulators; Experimental autoimmune prostatitis

向作者/读者索取更多资源

Chronic non bacterial prostatitis is a chronic inflammatory syndrome. Its etiology and physiopathology are unclear and treatments are empirical and ineffective in most cases. Autoimmunity has been proposed as an etiology. In the present report, we investigated the impact of vitamin D receptor silencing, by use of VDR-KO NOD mice and the immune-modulating effect of the vitamin D3 analog TX527 on the development of Experimental Autoimmune Prostatitis in NOD mice. VDR-KO NOD mice developed a more aggressive form of autoimmune prostatitis characterized by a greater lymphoproliferative response against prostate antigen in vitro (6.92 +/- 4.77 vs. 2.47 +/- 0.41 21 days after disease induction, p < 0.05) and higher levels of specific INF gamma secretion (471 +/- 6 vs. 386 +/- 5 pg/ml, p < 0.01). This was accompanied in vivo by more severe lesions and augmented mononuclear cell infiltration in the prostate gland. On the other hand, although analog-treated mice showed a significant reduction in the spleen T-cell specific proliferative response against prostate antigen in vitro, no effect on disease development was observed. We conclude that vitamin D receptor modulation holds the promise of interfering with autoimmune prostatitis. Introduction of more powerful analogs, or combinations with anti-T-cell reagents may represent therapeutic solutions for these group of patients. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Endocrinology & Metabolism

Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes

Athena Philis-Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell-Jones, Julio Rosenstock

Summary: This article describes the clinical development program ONWARDS phase 3a, which investigates the use of once-weekly basal insulin icodec in the treatment of type 2 and type 1 diabetes. Six trials are being conducted to evaluate the efficacy and safety of icodec, with consideration of different clinical scenarios and comparator treatments.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Low Gestational Weight Gain in Women With Gestational Diabetes Is Safe With Better Metabolic Profile Postpartum

Caro Minschart, Astrid Lammertyn, Paul Van Crombrugge, Carolien Moyson, Johan Verhaeghe, Sofie Vandeginste, Hilde Verlaenen, Chris Vercammen, Toon Maes, Els Dufraimont, Nele Roggen, Christophe De Block, Yves Jacquemyn, Farah Mekahli, Katrien De Clippel, Annick Van Den Bruel, Anne Loccufier, Annouschka Laenen, Roland Devlieger, Chantal Mathieu, Katrien Benhalima

Summary: The level of gestational weight gain (GWG) during pregnancy is associated with adverse pregnancy outcomes in women with gestational diabetes (GDM) compared to women with normal glucose tolerance (NGT). Low GWG below recommended levels frequently occurs in GDM women without increased risk for adverse outcomes. Excessive GWG is associated with increased risk for neonatal hypoglycemia and worse metabolic profile postpartum in GDM women, and with higher rates of instrumental delivery and larger infants in NGT women.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Editorial Material Endocrinology & Metabolism

Applying the WHO global targets for diabetes mellitus

Alice Y. Y. Cheng, Marilia Brito Gomes, Sanjay Kalra, Andre-Pascal Kengne, Chantal Mathieu, Jonathan E. Shaw

Summary: In 2022, the WHO established the first global targets for diabetes mellitus. These targets aim to achieve, by 2030, that 80% of people with diabetes mellitus are diagnosed, 80% of those with diabetes mellitus have good control of blood sugar and blood pressure, 60% of those over 40 receive statin treatment, and 100% of those with type 1 diabetes mellitus have access to affordable insulin and blood glucose monitoring.

NATURE REVIEWS ENDOCRINOLOGY (2023)

Review Cardiac & Cardiovascular Systems

Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society

Andrea M. Yeung, Jingtong Huang, Ambarish Pandey, Ibrahim A. Hashim, David Kerr, Rodica Pop-Busui, Connie M. Rhee, Viral N. Shah, Lia Bally, Antoni Bayes-Genis, Yong Mong Bee, Richard Bergenstal, Javed Butler, G. Alexander Fleming, Gregory Gilbert, Stephen J. Greene, Mikhail N. Kosiborod, Lawrence A. Leiter, Boris Mankovsky, Thomas W. Martens, Chantal Mathieu, Viswanathan Mohan, Kershaw Patel, Anne Peters, Eun-Jung Rhee, Giuseppe M. C. Rosano, David B. Sacks, Yader Sandoval, Jane Jeffrie Seley, Oliver Schnell, Guillermo Umpierrez, Kayo Waki, Eugene E. Wright Jr, Alan H. B. Wu, David C. Klonoff

Summary: The Diabetes Technology Society assembled a panel of clinician experts to review the current evidence on biomarker screening of people with diabetes for heart failure and provide recommendations for diagnosis and management to prevent disease progression.

PROGRESS IN CARDIOVASCULAR DISEASES (2023)

Article Obstetrics & Gynecology

Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial - study protocol

Kaat Beunen, Nancy Van Wilder, Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, Xavier-Philippe Aers, Frank Nobels, Joke Marlier, Dahae Lee, Joke Cuypers, Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Katrien Benhalima

Summary: This study aims to evaluate the efficacy, safety and cost-effectiveness of the MiniMed (TM) 780G HCL system in pregnant women with T1D. It is an international, open-label, randomized controlled trial that will compare the MiniMed (TM) 780G HCL system to standard of care. The primary outcome is the time spent within the pregnancy glucose target range.

BMC PREGNANCY AND CHILDBIRTH (2023)

Review Endocrinology & Metabolism

Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets

Katrien Benhalima, Kaat Beunen, Sarah E. Siegelaar, Rebecca Painter, Helen R. Murphy, Denice S. Feig, Lois E. Donovan, Sarit Polsky, Elizabeth Buschur, Carol J. Levy, Yogish C. Kudva, Tadej Battelino, Lene Ringholm, Elisabeth R. Mathiesen, Chantal Mathieu

Summary: Maintaining glucose concentrations within target, appropriate gestational weight gain, lifestyle management, and using antihypertensive treatment and low-dose aspirin if necessary can reduce the risk of complications in pregnancies complicated by type 1 diabetes. Hybrid closed-loop insulin delivery systems show promise as a treatment option during pregnancy.

LANCET DIABETES & ENDOCRINOLOGY (2023)

Article Endocrinology & Metabolism

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Hiddo J. L. Heerspink, Andreas L. Birkenfeld, David Z. I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill

Summary: This study aims to evaluate the efficacy and safety of Finerenone in type 1 diabetes and chronic kidney disease (CKD). Finerenone could potentially become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Article Endocrinology & Metabolism

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

Chantal Mathieu, Alice Wiedeman, Karen Cerosaletti, S. Alice Long, Elisavet Serti, Laura Cooney, Joan Vermeiren, Silvia Caluwaerts, Karolien Van Huynegem, Lothar Steidler, Sven Blomme, Pieter Rottiers, Gerald T. Nepom, Kevan C. Herold

Summary: The oral delivery of AG019 was found to be well tolerated and safe as a monotherapy and in combination with teplizumab in patients with type 1 diabetes. The treatment did not interfere with the safety profile of teplizumab and may have additional biological effects, including changes in preproinsulin-specific T cells. Preliminary data support further studies with AG019 alone or in combination with teplizumab or other systemic immunotherapies for type 1 diabetes.

DIABETOLOGIA (2023)

Review Endocrinology & Metabolism

Incretins beyond type 2 diabetes

Chantal Mathieu, Iraj Ahmadzai

Summary: This review examines the use of GLP-1 receptor agonists, specifically in type 1 diabetes, and concludes that they can lower weight and required insulin doses. However, their effects on glucose control and hypoglycemia vary depending on study protocols. Side effects include gastrointestinal complaints. The potential use of GLP-1 receptor agonists in other forms of diabetes is briefly discussed, but current evidence is limited.

DIABETOLOGIA (2023)

Article Endocrinology & Metabolism

Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory

Robert Moulder, Tommi Valikangas, M. Karoliina Hirvonen, Tomi A. Suomi, Caroline A. Brorsson, Niina Lietzen, Sylvaine F. A. Bruggraber, Lut Overbergh, David B. Dunger, Mark Peakman, Piotr J. Chmura, Soren Brunak, Anke M. Schulte, Chantal Mathieu, Mikael Knip, Laura L. Elo, Riitta Lahesmaa

Summary: There is a growing need for markers that could indicate the decline in beta cell function in type 1 diabetes. This study evaluated a panel of proteins in serum from newly diagnosed individuals and found associations between certain proteins and beta cell function. The findings suggest that these proteins may be useful in future studies of beta cell function in type 1 diabetes.

DIABETOLOGIA (2023)

Editorial Material Endocrinology & Metabolism

Time for changes in type 1 diabetes intervention trial designs

Mark A. Atkinson, Michael J. Haller, Desmond A. Schatz, Manuela Battaglia, Chantal Mathieu

LANCET DIABETES & ENDOCRINOLOGY (2023)

Article Endocrinology & Metabolism

Precision medicine for cardiometabolic disease: a framework for clinical translation

Paul W. Franks, William T. Cefalu, John Dennis, Jose C. Florez, Chantal Mathieu, Robert W. Morton, Martin Ridderstrale, Henrik H. Sillesen, Coen D. A. Stehouwer

Summary: Cardiometabolic disease poses a major threat to global health. Precision medicine has the potential to reduce the burden of this disease cluster and improve evidence-based medicine. It requires a well functioning system involving various stakeholders and relies on powerful computing infrastructure and research methods for analysis of large-scale data.

LANCET DIABETES & ENDOCRINOLOGY (2023)

Meeting Abstract Endocrinology & Metabolism

EVALUATION OF SENSOR-MEASURED OUTCOMES IN ADULTS WITH TYPE 1 DIABETES SWITCHING TO INSULIN GLARGINE 300 U/ML: A RETROSPECTIVE, PROPENSITY-SCORE MATCHED STUDY

S. Charleer, S. Fieuws, T. Boone, C. De Block, N. Bolsens, F. Nobels, K. Mikkelsen, C. Mathieu, P. Gillard

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Meeting Abstract Endocrinology & Metabolism

REAL-WORLD 24-MONTH IMPACT OF INTERMITTENTLY-SCANNED CONTINUOUS GLUCOSE MONITORING IN ADULTS WITH TYPE 1 DIABETES LIVING WITH NORMAL OR IMPAIRED AWARENESS OF HYPOGLYCEMIA

S. Charleer, C. De Block, N. Bolsens, L. Van Huffel, F. Nobels, C. Mathieu, P. Gillard

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Meeting Abstract Endocrinology & Metabolism

THE EVIDENCE FOR ALTERNATIVE MONITORING TECHNOLOGIES

C. Mathieu

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Article Immunology

Isolation and characterisation of PR3-specific B cells and their immunoglobulin sequences

Shane Kelly, Katherine J. L. Jackson, Timothy J. Peters, Dan Suan, Christopher C. Goodnow

Summary: This study successfully identified and characterized PR3-specific B cells from the peripheral blood of patients with PR3 autoantibodies. These cells exhibited specific immunological features, suggesting that PR3 self-reactivity may occur early in B-cell development.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

Targeting NF-κB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis

Ana Merino-Vico, Jan Piet van Hamburg, Paul Tuijnenburg, Giulia Frazzei, Aram Al-Soudi, Carlo G. Bonasia, Boy Helder, Abraham Rutgers, Wayel H. Abdulahad, Coen A. Stegeman, Jan-Stephan Sanders, Laura Bergamaschi, Paul A. Lyons, Theo Bijma, Laura van Keep, Kirsten Wesenhagen, Aldo Jongejan, Henric Olsson, Niek de Vries, Taco W. Kuijpers, Peter Heeringa, Sander W. Tas

Summary: B lineage cells play a critical role in ANCA-associated vasculitis (AAV), and the transcription factor NF-kappa B may be a potential therapeutic target for AAV and other autoimmune diseases with prominent B cell involvement.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

K2P2.1 is a regulator of inflammatory cell responses in idiopathic inflammatory myopathies

Christopher Nelke, Thomas Muentefering, Derya Cengiz, Lukas Theissen, Vera Dobelmann, Christina B. Schroeter, Helena Block, Corinna Preu, Alexander P. E. Michels, Stefanie Lichtenberg, Marc Pawlitzki, Steffen Pfeuffer, Niklas Huntemann, Alexander Zarbock, Thorben Briese, Christoph Kittl, Carsten Dittmayer, Thomas Budde, Ingrid E. Lundberg, Werner Stenzel, Sven G. Meuth, Tobias Ruck

Summary: K2P2.1 plays a regulatory role in the autoimmune response of idiopathic inflammatory myopathies (IIMs), by regulating inflammatory cell response, adhesion, and transmigration in both endothelial and skeletal muscle cells. Inhibiting K2P2.1 enhances the inflammatory response, while activating K2P2.1 improves the disease course.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

2023 International Consensus Guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis

Xuan Zhang, Jun Xia, Ying Jiang, David S. Pisetsky, Josef S. Smolen, Rong Mu, Shengming Dai, Michael E. Weinblatt, Tore K. Kvien, Juan Li, Thomas Doerner, Yu Zhang, Liwei Lu, Chengde Yang, Pingting Yang, Yuan Zhang, Chenchen Xu, Zhan Zhao, Peter E. Lipsky

Summary: The study suggests that TwHF may be as effective as MTX in treating active RA, and combination therapy may be more effective than monotherapy.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

Novel and unique rheumatoid factors cross-react with viral epitopes in COVID-19

Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, Zihao Zheng, Alex M. Robbins, S. Janna Bashar, Michael F. Denny, Sara S. Mccoy, Irene M. Ong, Miriam A. Shelef

Summary: Rheumatoid factors (RFs) are polyreactive antibodies that can bind disease-specific epitopes. Recent studies have found that RFs in COVID-19 can bind novel IgG epitopes, which provides new insights into the mechanism of RFs.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: A cohort study

Johanne Liberatore, Yann Nguyen, Jerome Hadjadj, Pascal Cohen, Luc Mouthon, Xavier Puechal, Loic Guillevin, Benjamin Terrier

Summary: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) can lead to decreased gammaglobulin levels, which is associated with an increased risk of relapse and severe infections. Older age, low gammaglobulin levels, and receiving pulses of methylprednisolone at induction therapy are risk factors for gammaglobulin decline.

JOURNAL OF AUTOIMMUNITY (2024)